<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1661">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04418505</url>
  </required_header>
  <id_info>
    <org_study_id>VL-2020-02</org_study_id>
    <nct_id>NCT04418505</nct_id>
  </id_info>
  <brief_title>Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms</brief_title>
  <acronym>COVIDLight</acronym>
  <official_title>A Randomized Study Evaluating the Efficacy of the Vielight RX Plus in the Treatment of COVID-19 Respiratory Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vielight Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vielight Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to obtain data on the efficacy of the Vielight RX Plus in&#xD;
      decreasing time to recovery of symptoms in subjects with COVID-19. The study will be&#xD;
      conducted among COVID-19 positive subjects at home in self-isolation via electronic data&#xD;
      collection (EDC). There will be no physical contact between the subjects and the Qualified&#xD;
      Investigator (QI) or other study staff. This study aims to demonstrate that the Vielight RX&#xD;
      Plus is a useful adjunct to standard of care (SOC). We hypothesize that the Vielight RX Plus&#xD;
      will accelerate recovery and reduce viral infection severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted entirely online. At no point will study staff be in direct contact&#xD;
      with participants. The study will be managed by an independent clinical research organization&#xD;
      (CRO), supporting a Qualified Investigator (QI). Vielight Inc will supply the RX Plus devices&#xD;
      free of charge and will sponsor the study.&#xD;
&#xD;
      Potential participants will be prompted to complete an online screening form if they are&#xD;
      interested in participating. During the screening, the potential participant will be asked to&#xD;
      upload a copy of their positive COVID-19 infection confirmation report and a valid ID. If the&#xD;
      potential subject qualifies for the study, by statisfying all inclusion and exclusion&#xD;
      criteria, the potential participant will then be prompted to complete an electronic informed&#xD;
      consent form (ICF) via the electronic data collection (EDC) platform and will be enrolled&#xD;
      into the study.&#xD;
&#xD;
      This is a 30-day, prospective, randomized study, with no blinding. 280 participants will be&#xD;
      randomized into two groups: Group 1: Standard of Care; Group 2: Standard of Care + Vielight&#xD;
      RX Plus treatment. In Group 2, the Vielight RX Plus will be administered for 20 minutes twice&#xD;
      a day, separated by at least 6 hours for the first 5 days. For the subsequent 25 days,&#xD;
      treatment will be once per day. The Vielight RX Plus will be positioned over the upper most&#xD;
      part of the breastbone to stimulate the thymus gland and within one nostril.&#xD;
&#xD;
      During each of the 30-days, participants will be asked to complete a questionnaire to assess&#xD;
      respiratory symptom severity, and log a daily dairy as well as oxygen saturation level (using&#xD;
      a portable oximeter).&#xD;
&#xD;
      The primary measure is time to overall recovery in days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to elimination of COVID-19 related symptoms</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days with mild COVID-19 related symptoms</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days with mild overall respiratory symptoms</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom reduction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination of symptoms</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of days with mild respiratory symptoms</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care + Vielight RX Plus Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vielight RX Plus</intervention_name>
    <description>The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.</description>
    <arm_group_label>Standard of Care + Vielight RX Plus Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmation of COVID-19 infection&#xD;
&#xD;
          -  Experiencing moderate to severe respiratory symptoms&#xD;
&#xD;
          -  Between 18-65 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for hospitalization at the time of diagnosis&#xD;
&#xD;
          -  Current need for supplemental oxygen or positive pressure support and/or has required&#xD;
             supplemental oxygen or positive pressure support for &gt;or= 24 hours&#xD;
&#xD;
          -  &gt;10 days since symptom onset&#xD;
&#xD;
          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Positive for Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) or Human&#xD;
             Immunodeficiency Virus&#xD;
&#xD;
          -  Inability to electronically complete study questionnaires in English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Berk</last_name>
    <phone>1-800-517-8010</phone>
    <email>info@covidlight.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander White, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Michael Zahavi</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H1G6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Berk</last_name>
    </contact>
    <contact_backup>
      <last_name>Nazanin Hosseinkhah, Ph.D.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Roy Tingley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://covidlight.ca</url>
    <description>Study website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Photobiomodulation</keyword>
  <keyword>Low level light therapy</keyword>
  <keyword>PBM</keyword>
  <keyword>Red light</keyword>
  <keyword>Near-infrared light</keyword>
  <keyword>At-home treatment</keyword>
  <keyword>Remote</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

